Details of the Drug Combination

General Information of Drug Combination (ID: DCEROKL)

Drug Combination Name

DFN-15 PMID28870136-Compound-43

Indication

Disease Entry	Status	REF
Colon adenocarcinoma	Investigative	[1]

Component Drugs

DFN-15 DM3BF9B

PMID28870136-Compound-43 DMWGV8N

N.A.

Small molecular drug

High-throughput Screening Result

Testing Cell Line: COLO 205

Zero Interaction Potency (ZIP) Score: 2.75

Bliss Independence Score: 4.03

Loewe Additivity Score: 1.67

LHighest Single Agent (HSA) Score: 0.43

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of DFN-15

Disease Entry	ICD 11	Status	REF
Migraine	8A80	Phase 3	[2]

PMID28870136-Compound-43 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Ecto-5'-nucleotidase (CD73)	TTK0O6Y	5NTD_HUMAN	Inhibitor	[3]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adult acute myeloid leukemia	DCU09YS	HL-60(TB)	Investigative	[4]
Adenocarcinoma	DCXZ7GH	DU-145	Investigative	[5]
Adenocarcinoma	DC71JW8	OVCAR3	Investigative	[5]
------------------------------------------------------------------------------------

References

1	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
4	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
5	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976